Borderline personality disorder: identification, comorbidity, and emerging treatment opportunities
- Authors: Zobin M.L.1
-
Affiliations:
- Centre of transformational therapy of addictions
- Issue: Vol LVII, No 2 (2025)
- Pages: 150-159
- Section: Discussions
- URL: https://journals.rcsi.science/1027-4898/article/view/312180
- DOI: https://doi.org/10.17816/nb677346
- EDN: https://elibrary.ru/VYZUFR
- ID: 312180
Cite item
Abstract
This article analyses the diagnostic criteria for borderline personality disorder as defined in the 5th edition of Diagnostic and Statistical Manual of Mental Disorders and the 11th revision of International Classification of Diseases. The combination of categorical and dimensional diagnostic models improves its validity, which meets the needs of clinical practice. At the same time, the heterogeneity and persistent conceptual ambiguity of borderline personality disorder are emphasized. The phenomenology of comorbidity between borderline and addictive disorders is considered as overlapping symptoms that exacerbate overall clinical presentation. Challenges in diagnosing borderline personality disorder are noted when constitutional symptoms are masked by the consequences of psychoactive substance use. The article offers a brief overview of current approaches to the treatment of borderline personality disorder, highlighting the potential of ketamine therapy. The results of our own retrospective open study of 18 patients with dual (borderline personality disorder + alcohol/cocaine use disorder) and triple (borderline personality disorder + alcohol/cocaine use disorder + depression) diagnosis who received ketamine treatment are discussed. Patients received three ketamine infusions over one week (0.5–0.75 mg/kg over 40 minutes), followed by a booster session one month later. Preliminary results of treatment are discussed, which are quite comparable with the effectiveness of specialized psychotherapy. These findings suggest that ketamine therapy may offer a novel perspective on the traditionally pessimistic therapeutic outlook for borderline personality disorder.
Full Text
##article.viewOnOriginalSite##About the authors
Mikhail L. Zobin
Centre of transformational therapy of addictions
Author for correspondence.
Email: dr.zobin@gmail.com
ORCID iD: 0000-0002-8239-3770
SPIN-code: 2440-1383
MD, Cand. Sci. (Medicine)
Russian Federation, Dobrota, MontenegroReferences
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. Arlington: American Psychiatric Association; 2013. ISBN: 978-0-89042-554-1
- Leichsenring F, Fonagy P, Heim N, et al. Borderline personality disorder: a comprehensive review of diagnosis and clinical presentation, etiology, treatment, and current controversies. World Psychiatry. 2024;23(1):4–25. doi: 10.1002/wps.21156
- WHO. ICD-11 Clinical descriptions and diagnostic guidelines for mental and behavioural disorders. Geneva: World Health Organisation; 2022. ISBN: 978-92-4-007726-3
- Bach B, Kramer U, Doering S, et al. The ICD-11 classification of personality disorders: a European perspective on challenges and opportunities. Bord Personal Disord Emot Dysregul. 2022;9(1):12. doi: 10.1186/s40479-022-00182-0
- Bohus M, Stoffers-Winterling J, Sharp C, et al. Borderline personality disorder. Lancet. 2021;398(10310):1528–1540. doi: 10.1016/S0140-6736(21)00476-1
- Gunderson JG, Herpertz SC, Skodol AE, et al. Borderline personality disorder. Nat Rev Dis Primers. 2018;4:18029. doi: 10.1038/nrdp.2018.29
- Shah R, Zanarini MC. Comorbidity of borderline personality disorder: current status and future directions. Psychiatr Clin N Am. 2018;41(4):583–593. doi: 10.1016/j.psc.2018.07.009
- Szerman N, Peris L. Personality disorders and addiction disorders. In: el-Guebaly N, Carrà G, Galanter M, editors. Textbook of Addiction Treatment: International Perspectives. Springer, Milano; 2015. Р. 2063–2083. doi: 10.1007/978-88-470-5322-9_120
- Trull TJ, Freeman LK, Vebares TJ, et al. Borderline personality disorder and substance use disorders: an updated review. Borderline Personal Disord Emot Dysregul. 2018;5:15. doi: 10.1186/s40479-018-0093-9
- Stetsiv K, McNamara IA, Nance M, Carpenter RW. The co-occurrence of personality disorders and substance use disorders. Curr Psychiatry Rep. 2023;25(11):545–554. doi: 10.1007/s11920-023-01452-6
- Szerman N, Torrens M, Maldonado R, et al. World association on dual disorders (WADD). addictive and other mental disorders: a call for a standardized definition of dual disorders. Transl Psychiatry. 2022;12(1):446. doi: 10.1038/s41398-022-02212-5
- Maremmani A, Maremmani I. It’s time to admit the existence of a psychopathology specific to addiction. Neurology Bulletin. 2025;57(1):5–11. doi: 10.17816/nb637368
- Chapman J, Jamil RT, Fleisher C, Torrico TJ. Borderline personality disorder. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
- Trull TJ, Jahng S, Tomko RL, et al. Revised NESARC personality disorder diagnoses: gender, prevalence, and comorbidity with substance dependence disorders. J Pers Disord. 2010;24(4):412–426. doi: 10.1521/pedi.2010.24.4.412
- Parmar A, Kaloiya G. Comorbidity of personality disorder among substance use disorder patients: a narrative review. Indian J Psychol Med. 2018;40(6):517–527. doi: 10.4103/IJPSYM.IJPSYM_164_18
- Jahng S, Trull TJ, Wood PK, et al. Distinguishing general and specific personality disorder features and implications for substance dependence comorbidity. J Abnorm Psychol. 2011;120(3):656–669. doi: 10.1037/a0023539
- Fraser R, Isaif L, Teles D, Laporte L. Personality disorders and addiction disorders. In: el-Guebaly N, Carrà G, Galanter M, Baldacchino AM, editors. Textbook of Addiction Treatment. Springer, Cham; 2021. doi: 10.1007/978-3-030-36391-8_96
- Mulder RT, Horwood LJ, Tyrer P. The borderline pattern descriptor in the International Classification of Diseases, 11th Revision: A redundant addition to classification. Aust N Z J Psychiatry. 2020;54(11):1095–1100. doi: 10.1177/0004867420951608
- Gutiérrez F, Aluja A, Ruiz Rodríguez J, et al. Borderline, where are you? A psychometric approach to the personality domains in the International Classification of Diseases, 11th Revision (ICD-11). Personal Disord. 2023;14(3):355–359. doi: 10.1037/per0000592
- Caspi A, Houts RM, Belsky DW, et al. The p factor: one general psychopathology factor in the structure of psychiatric disorders? Clin Psychol Sci. 2014;2(2):119–137. doi: 10.1177/2167702613497473
- Gluschkoff K, Jokela M, Rosenström T. General psychopathology factor and borderline personality disorder: Evidence for substantial overlap from two nationally representative surveys of U.S. adults. Personal Disord. 2021;12(1):86–92. doi: 10.1037/per0000405
- Sharp C, Wall K. DSM-5 level of personality functioning: refocusing personality disorder on what it means to be human. Annu Rev Clin Psychol. 2021;17:313-337. doi: 10.1146/annurev-clinpsy-081219-105402
- Zanarini MC, Temes CM, Frankenburg FR, et al. Description and prediction of time-to-attainment of excellent recovery for borderline patients followed prospectively for 20 years. Psychiatry Res. 2018;262:40–45. doi: 10.1016/j.psychres.2018.01.034
- Clinical guidelines: Specific personality disorders. 2024–2025–2026 (23.08.24). Approved by the Ministry of Health of the Russian Federation. (In Russ.) URL: http://disuria.ru/_ld/14/1459_kr24F60F61MZ.pdf
- National Institute for Health and Care Excellence. Borderline personality disorder: recognition and management. Clinical guideline. London: National Institute for Health and Care Excellence; 2009. URL: https://www.nice.org.uk/guidance/cg78
- Simonsen S, Bateman A, Bohus M, et al. European guidelines for personality disorders: past, present and future. Borderline Personal Disord Emot Dysregul. 2019;6:9. doi: 10.1186/s40479-019-0106-3
- Cristea IA, Gentili C, Cotet CD, et al. Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74(4):319–328. doi: 10.1001/jamapsychiatry.2016.4287
- Smits ML, Luyten P, Feenstra DJ, et al. Trauma and outcomes of mentalization-based therapy for individuals with borderline personality disorder. Am J Psychother. 2022;75(1):12–20. doi: 10.1176/appi.psychotherapy.20210027
- Setkowski K, Palantza C, van Ballegooijen W, et al. Which psychotherapy is most effective and acceptable in the treatment of adults with a (sub)clinical borderline personality disorder? A systematic review and network meta-analysis. Psychol Med. 2023;53(8):3261–3280. doi: 10.1017/S0033291723000685
- Woodbridge J, Townsend M, Reis S, et al. Non-response to psychotherapy for borderline personality disorder: A systematic review. Aust N Z J Psychiatry. 2022;56(7):771–787. doi: 10.1177/00048674211046893
- Gartlehner G, Crotty K, Kennedy S, et al. Pharmacological treatments for borderline personality disorder: A systematic review and meta-analysis. CNS Drugs. 2021;35(10):1053–1067. doi: 10.1007/s40263-021-00855-4
- Stoffers J, Völlm BA, Rücker G, et al. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010;(6):CD005653. doi: 10.1002/14651858.CD005653.pub2
- Pascual JC, Arias L, Soler J. Pharmacological management of borderline personality disorder and common comorbidities. CNS Drugs. 2023;37(6):489–497. doi: 10.1007/s40263-023-01015-6
- Yavi M, Lee H, Henter ID, et al. Ketamine treatment for depression: a review. Discov Ment Health. 2022;2(1):9. doi: 10.1007/s44192-022-00012-3
- Jones JL, Mateus CF, Malcolm RJ, et al. Efficacy of ketamine in the treatment of substance use disorders: a systematic review. Front Psychiatry. 2018;9:277. doi: 10.3389/fpsyt.2018.00277
- Dakwar E, Nunes EV, Hart CL, et al. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. Neuropharmacology. 2018;142:270–276. doi: 10.1016/j.neuropharm.2018.01.005
- Walsh Z, Mollaahmetoglu OM, Rootman J, et al. Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open. 2021;8(1):e19. doi: 10.1192/bjo.2021.1061
- Drozdz SJ, Goel A, McGarr MW, et al. Ketamine assisted psychotherapy: A systematic narrative review of the literature. J Pain Res. 2022;15:1691–1706. doi: 10.2147/JPR.S360733
- Danayan K, Chisamore N, Rodrigues NB, et al. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder. Psychiatry Res. 2023;323:115133. doi: 10.1016/j.psychres.2023.115133
- McIntyre RS, Lipsitz O, Rodrigues NB, et al. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. Bipolar Disord. 2020;22(8):831–840. doi: 10.1111/bdi.12941
- Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: A midazolam controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327–335. doi: 10.1176/ appi.ajp.2017.17060647
- Lengvenyte A, Olie E, Courtet P. Suicide has many faces, so does ketamine: a narrative review on Ketamine's antisuicidal actions. Curr Psychiatry Rep. 2019;21(12):132. doi: 10.1007/s11920-019-1108-y
- Nandan NK, Soni PK, Parsaik A, Hashmi A. "Esketamine" in borderline personality disorder: a look beyond suicidality. Cureus. 2022;14(4):e24632. doi: 10.7759/cureus.24632
- Rogg H, Avram M, Müller F, et al. Ketamine as a treatment option for severe borderline personality disorder: a case report. J Clin Psychopharmacol. 2023;43(1):64–65. doi: 10.1097/JCP.0000000000001642
- Fineberg SK, Choi EY, Shapiro-Thompson R, et al. A pilot randomized controlled trial of ketamine in borderline personality disorder. Neuropsychopharmacology. 2023;48(7):991–999. doi: 10.1038/s41386-023-01540-4
- Więdłocha M, Marcinowicz P, Komarnicki J, et al. Depression with comorbid borderline personality disorder — could ketamine be a treatment catalyst? Front Psychiatry. 2024;15:1398859. doi: 10.3389/fpsyt.2024.1398859
- Wöller W, Huppertz BJ. Borderline — eine diagnostische Einheit? [Borderline — a diagnostic entity?]. Fortschr Neurol Psychiatr. 1984;52(10):338–345. doi: 10.1055/s-2007-1002031
- Vanicek T, Unterholzner J, Lanzenberger R, et al. Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder. World J Biol Psychiatry. 2022;23(9):715–718. doi: 10.1080/15622975.2022.2031287
- Krupitsky E, Burakov A, Romanova T, et al. Ketamine psychotherapy for heroin addiction: immediate effects and two-year followup. J Subst Abuse Treat. 2002;23(4):273–283. doi: 10.1016/S0740-5472(02)00275-1
- Rothberg RL, Azhari N, Haug NA, Dakwar E. Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. J Psychopharmacol. 2021;35(2):150–158. doi: 10.1177/0269881120970879
- Chiappini S, d'Andrea G, De Filippis S, et al. Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. Eur Neuropsychopharmacol. 2023;74:15–21. doi: 10.1016/j.euroneuro.2023.04.01 145
- Mollaahmetoglu OM, Keeler J, Ashbullby KJ, et al. “This is something that changed my life”: A qualitative study of patients’ experiences in a clinical trial of ketamine treatment for alcohol use disorders. Front Psychiatry. 2021;12:695335. doi: 10.3389/fpsyt.2021.695335
- Nielson EM, May DG, Forcehimes AA, Bogenschutz MP. The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions. Front Pharmacol. 2018;9:132. doi: 10.3389/fphar.2018.00132
- Hutsebaut J, Bender DS. The clinical utility of the level of personality functioning scale: a treatment perspective. J Psychiatr Pract. 2024;30(6):411–420. doi: 10.1097/PRA.0000000000000822
- Kleindienst N, Jungkunz M, Bohus M. A proposed severity classification of borderline symptoms using the borderline symptom list (BSL-23). Borderline Personal Disord Emot Dysregul. 2020;7(1):11. doi: 10.1186/s40479-020-00126-6
- Unoka Z, Csáky-Pallavicini K, Horváth Z, et al. The Inventory of personality organization: A valid instrument to detect the severity of personality dysfunction. Front Psychiatry. 2022;13:995726. doi: 10.3389/fpsyt.2022.995726
- Gren J, Gorman I, Ruban A, et al. Call for evidence-based psychedelic integration. Exp Clin Psychopharmacol. 2024;32(2):129–135. doi: 10.1037/pha0000684
- Iliakis EA, Ilagan GS, Choi-Kain LW. Dropout rates from psychotherapy trials for borderline personality disorder: a meta-analysis. Personal Disord. 2021;12(3):193–206. doi: 10.1037/per0000453
- Leichsenring F, Sarrar L, Steinert C. Drop-outs in psychotherapy: a change of perspective. World Psychiatry. 2019;18(1):32–33. doi: 10.1002/wps.20588
- Sicorello M, Schmahl C. Emotion dysregulation in borderline personality disorder: A fronto-limbic imbalance? Curr Opin Psychol. 2021;37:114–120. doi: 10.1016/j.copsyc.2020.12.002
- Romeo B, Hermand M, Pétillion A, et al. Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. J Psychiatr Res. 2021;137:273–282. doi: 10.1016/j.jpsychires.2021.03.002
- Varela FJ, Thompson ET, Rosch E. The embodied mind: cognitive science and human experience. MIT press; 1993. 308 p.
- Davidson D. The material mind. Essays on actions and events. New York: Oxford University Press; 2001. 346 p.
- Tyrer P, Mulder R, Kim YR, Crawford MJ. The development of the ICD-11 classification of personality disorders: an amalgam of science, pragmatism, and politics. Annu Rev Clin Psychol. 2019;15:481–502. doi: 10.1146/annurev-clinpsy-050718-095736
Supplementary files
